Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

BACKGROUND: This study evaluates patient-reported outcomes (PROs) in a double-blind, phase III study of baricitinib as monotherapy or combined with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with no or minimal prior conventional synthetic disease-modifying antirheumatic dru...

Descripción completa

Detalles Bibliográficos
Autores principales: Schiff, Michael, Takeuchi, Tsutomu, Fleischmann, Roy, Gaich, Carol L., DeLozier, Amy M., Schlichting, Douglas, Kuo, Wen-Ling, Won, Ji-Eon, Carmack, Tara, Rooney, Terence, Durez, Patrick, Shaikh, Saeed, Hidalgo, Rodolfo Pardo, van Vollenhoven, Ronald, Zerbini, Cristiano A. F.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604362/
https://www.ncbi.nlm.nih.gov/pubmed/28923098
http://dx.doi.org/10.1186/s13075-017-1410-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604362/
https://www.ncbi.nlm.nih.gov/pubmed/28923098
http://dx.doi.org/10.1186/s13075-017-1410-1

Ejemplares similares